• About us
    • About Lindahl
    • How we work
    • Said about Lindahl
    • Press
    • Find us
    • Privacy
  • Areas
    • Commercial dispute resolution
    • IT/Tech
    • Intellectual property
    • Life Sciences
    • M&A
    • All areas
  • Our people
    • Stockholm
    • Göteborg
    • Malmö
    • Uppsala
    • Helsingborg
    • Örebro
  • Latest news
    • Cases and transactions
    • News
    • Events
    • Knowledge
    • Portraits
  • Offices
    • Stockholm
    • Göteborg
    • Malmö
    • Uppsala
    • Örebro
    • Helsingborg

Lindahl advises Intervacc in its rights issue

  • Home
  • Latest news
  • Cases and transactions
  • 2018
  • Lindahl advises Intervacc in its rights issue

Advokatfirman Lindahl advises Intervacc AB (publ), listed on Nasdaq First North in connection with its rights issue of approximately MSEK 61.

The board of directors of Intervacc has resolved to increase the company’s share capital through an issue of shares with preferential rights for existing shareholders. The rights issue is subject to the approval by an extraordinary general meeting to be held on 9 March 2018. Upon full subscription of the rights issue, Intervacc will receive approximately MSEK 61, before deduction of transaction costs. The rights issue is guaranteed to an amount corresponding to approximately 80 per cent of the rights issue by guarantee commitments. The rights issue is carried out in order to enable Intervacc to further develop from being primarily a research and development company with Strangvac® as the main product, into a commercial production phase with a wide portfolio of vaccine development projects and to continue building a strong sales and marketing organisation.

Intervacc is a Swedish company within the biotechnology sector. The company’s main object is to develop modern sub-unit vaccines against economically important bacterial infections, mainly within animal health. The company’s vaccine candidates are based on several years of research at the Karolinska Institute and the Swedish University of Agricultural Research where the foundation was laid for the company’s research and development work.

Advokatfirman Lindahl assists Intervacc in the transaction with client relationship partner Per Hedman (Life Science) and partner in charge of the project Maria Arnoldsson (Capital Markets and public M&A), Anton Knifström, Oliver Kronberg and Mimi Hörnmo (Capital Markets and public M&A), Anders Burén (Life Science), and Anna Romell Stenmark, Isabella Rosman and Åsa Fahlén (Tax).

Contact

  • Anna Romell Stenmark

    Uppsala

    anna.romell.stenmark@lindahl.se +46 705 261 863
  • Åsa Fahlén

    Uppsala

    asa.fahlen@lindahl.se +46 708 340 648
Pages
  • Start
  • About us
  • Areas
  • Our people
  • Latest news
  • Privacy
Our offices
  • Stockholm reception.stockholm@lindahl.se +46 8 527 70 800
  • Göteborg reception.goteborg@lindahl.se +46 31 799 10 00
  • Malmö reception.malmo@lindahl.se +46 40 664 66 50
  • Uppsala reception.uppsala@lindahl.se +46 18 16 18 50
  • Örebro reception.orebro@lindahl.se +46 19 20 89 00
  • Helsingborg reception.helsingborg@lindahl.se +46 42 17 53 00
Social media
  • Connect with us on social networks: Instagram, Linkedin, Youtube, Facebook,

Disclaimer

The material and information on this site is intended for general informational purposes only and does not constitute legal advice on any specific matter. Please note that all images on Lindahl's website, www.lindahl.se, are subject to intellectual property protection and downloading, publication, copying and/or other use of the images requires the written consent of the rights holder. You'll find Advokatfirman Lindahl KB's general terms and conditions here.

Some cookies are essential, others help us improve your experience by providing insights into how the site is used. For more information, please visit our Cookie Policy.

Essential Cookies

These cookies are necessary for the functionality of the site and cannot be disabled.

Analytics Cookies>

We use Analytics cookies to collect information that gives us insight into how our website is being used. We anonymize IP addresses in Google Analytics. By clicking on Decline we won't save theese cookies.

Decline
We use cookies to get insights on how our site is used and give our visitors the best possible experience